Literature DB >> 2458949

Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor.

S J Green1, G Tarone, C B Underhill.   

Abstract

To examine the role of the hyaluronate receptor in cell to cell adhesion, we have employed the K-3 monoclonal antibody (MAb) which specifically binds to the hyaluronate receptor and blocks its ability to interact with hyaluronate. In the first set of experiments, we investigated the spontaneous aggregation of SV-3T3 cells, which involves two distinct mechanisms, one of which is dependent upon the presence of divalent cation and the other is independent. The divalent cation-independent aggregation was found to be completely inhibited by both intact and Fab fragments of the K-3 MAb. In contrast, the K-3 MAb had no effect on the divalent cation-dependent aggregation of cells. In a second set of experiments, we examined alveolar macrophages. The presence of hyaluronate receptors on alveolar macrophages was demonstrated by the fact that detergent extracts of these cells could bind [3H]hyaluronate, and this binding was blocked by the K-3 MAb. Immunoblot analysis of alveolar macrophages showed that the hyaluronate receptor had a Mr of 99,500, which is considerably larger than the 85,000 Mr for that on BHK cells. When hyaluronate was added to suspensions of alveolar macrophages, the cells were induced to aggregate. This effect was inhibited by the K-3 MAb, suggesting that the hyaluronate-induced aggregation was mediated by the receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458949     DOI: 10.1016/0014-4827(88)90393-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  15 in total

Review 1.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

2.  Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44.

Authors:  D M Kamikura; H Khoury; C Maroun; M A Naujokas; M Park
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

3.  Purification and characterization of a hyaluronan-binding protein from rat chondrosarcoma.

Authors:  M V Crossman; R M Mason
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

4.  Comparative stemness and differentiation of luminal and basal breast cancer stem cell type under glutamine-deprivation.

Authors:  Heena Jariyal; Chanchal Gupta; Shambhavi Andhale; Sonali Gadge; Akshay Srivastava
Journal:  J Cell Commun Signal       Date:  2021-01-28       Impact factor: 5.782

Review 5.  CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.

Authors:  L Y Bourguignon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

Review 6.  CD44 cell adhesion molecules.

Authors:  S Goodison; V Urquidi; D Tarin
Journal:  Mol Pathol       Date:  1999-08

7.  CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis.

Authors:  Jaklien C Leemans; Sandrine Florquin; Mirjam Heikens; Steven T Pals; Ronald van der Neut; Tom Van Der Poll
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Mitogen-activated protein kinases mediate Mycobacterium tuberculosis-induced CD44 surface expression in monocytes.

Authors:  Natarajan Palaniappan; S Anbalagan; Sujatha Narayanan
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

9.  Endocytosis of hyaluronan in rat Kupffer cells.

Authors:  J Alston-Smith; H Pertoft; T C Laurent
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

10.  Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages.

Authors:  P W Noble; F R Lake; P M Henson; D W Riches
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.